Anti-Obesity Prescription Drugs Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Size, Share & Trends, Drivers, Restraints, Opportunities, Manufacturer, Applications, And Segments

  • AMR-1063838
  • May 2021
  • Pharmaceuticals
  • 124 Pages
The global Anti-Obesity Prescription Drugs market research report provides complete study and detail analysis of the market. This study includes forecast analysis of the market which is based on global and regional level, whereas the research reports the provides forecast data from 2020-2028 and historic of 2018 and 2019. All the values are based on revenue USD Million. Moreover, the market research report describes various segments of the Anti-Obesity Prescription Drugs market based on its types, applications and end-use industry. The applications of the market are explained in different industry verticals with reference to major countries across the globe. Along with this, the research report also covers all the major players that are operating in the global Anti-Obesity Prescription Drugs market. These major players of the market are further studied and analyzed based on various parameters, such as annual market revenue, annual sales of the company, marketing strategy, historic growth and shipment volumes. Based on all the company’s insights, the market research analyst also suggests business strategy and marketing plans for improving the market position of existing participants of Anti-Obesity Prescription Drugs market.
 
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2020
Forecast Period Covered 2020 – 2028
Units for value Revenue in USD million and CAGR from 2020 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Companies Covered BRISTOL-MYERS SQUIBB CO., TAKEDA PHARMACEUTICAL, EISAI COMPANY, GLAXOSMITHKLINE PLC, PFIZER INC, SHIONOGI USA INC, VIVUS INC, ZAFGEN INC, NORGINE BV, BOEHRINGER INGELHEIM GMBH., 7TM PHARMA, ZYDUS CADILA, AKRIMAX PHARMACEUTICALS, ZEALAND PHARMA, ARROWHEAD RESEARCH
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa

COVID-19 Impact Analysis
The analysis of covid-19 is based on the impact of the current pandemic situation on market scenarios. This includes impact of covid-19 outbreak on overall revenue, market segments as well as regional market. The report also puts light on detailed impact analysis by taking into consideration all the government policies imposed during the pandemic situation, temporary shutdown of manufacturing units, current state of supply chain and distributors, and its future impacts on the growth of overall market. The market study will assist user to understand the global demand and impose strategic business plans to compete with the peers.

Apart from this, the market research report also covers drivers and restraints for the global Anti-Obesity Prescription Drugs market and their impact on the demand and supply during the forecast period. Along with this, the research report also provides Anti-Obesity Prescription Drugs market trends and opportunities that are based on regional and global level. Furthermore, the market research report also provides the major distributors and manufacturers that are operating in all the key region across the world. The researched data provided in the report is widely used by various industry players to strengthen their distribution channel and improve the geographical reach. In addition, the report also covers all the major players of the global Anti-Obesity Prescription Drugs market and its key offerings and solutions. The report also provides recent mergers and acquisitions of these key players.

The data which is provided in the market research report is analyzed and evaluated with the help of various marketing tools, such as SWOT analysis, Poster’s Five Force analysis, PESTEL analysis, value chain analysis, player positioning analysis and market share analysis. Therefore, this analysis tools helps the analyst to evaluate the Anti-Obesity Prescription Drugs market based on various parameters such as capital investments, impact of consumer’s preferences, economies of scale, manufacturing rights and patents, existing distribution channels, switching costs, government regulations and brand loyalty.

Major Key Players for Global Anti-Obesity Prescription Drugs Market:
The Anti-Obesity Prescription Drugs market research report offers the company profile of major key players including progress trends, competitive landscape breakdown, and key in regions development status. BRISTOL-MYERS SQUIBB CO., TAKEDA PHARMACEUTICAL, EISAI COMPANY, GLAXOSMITHKLINE PLC, PFIZER INC, SHIONOGI USA INC, VIVUS INC, ZAFGEN INC, NORGINE BV, BOEHRINGER INGELHEIM GMBH., 7TM PHARMA, ZYDUS CADILA, AKRIMAX PHARMACEUTICALS, ZEALAND PHARMA, ARROWHEAD RESEARCH

Anti-Obesity Prescription Drugs Market Segment Analysis:
By Mechanism of Action
Peripherally Acting Drugs
Centrally Acting Drugs
Drug Class
Bupropion and Naltrexone
Orlistat
Lorcaserin
Phentermine and Topiramate
Liraglutide
Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Geographic Coverage for Anti-Obesity Prescription Drugs Market:
The market research report on global Anti-Obesity Prescription Drugs market offers complete analysis across various regions across the world. The Anti-Obesity Prescription Drugs market is distributed into various regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa. The global leading market share as per the region is evaluated after considering Anti-Obesity Prescription Drugs market revenue, sales, shares, recent developments, innovations and growth rates. This section of regional analysis provides widespread evaluation of the industry from various countries and regions.

North America Anti-Obesity Prescription Drugs Market Value and Forecast
  • US
  • Canada
Europe Anti-Obesity Prescription Drugs Market Value and Forecast
  • UK
  • Germany
  • France
  •  Rest of Europe
Asia Pacific Anti-Obesity Prescription Drugs Market Value and Forecast
  • China
  • Japan
  • India
  • Rest of Asia Pacific
Latin America Anti-Obesity Prescription Drugs Market Value and Forecast
  • Mexico
  • Brazil
  • Rest of Latin America
Middle East and Africa Anti-Obesity Prescription Drugs Market Value and Forecast
  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa


Key highlights of the Anti-Obesity Prescription Drugs market report:
  • The report provides key trends of the global Anti-Obesity Prescription Drugs market
  • The report also covers consumer preferences and current industry growth
  • Key products or solutions offered by the main players in the Anti-Obesity Prescription Drugs industry
  • The report covers all the recent developments of the Anti-Obesity Prescription Drugs market and helps to provide current industry updates
  • The report covers a detailed look over the global Anti-Obesity Prescription Drugs Industry and provides with significant actionable insights
  • The Anti-Obesity Prescription Drugs market estimation from 2020-2028 and historical data for 2018 and 2019
  • The market study also provides data on changing market dynamics, market intelligence, current and future market trends
  • The report also analyses the microeconomic and macroeconomic factors that are affecting the global Anti-Obesity Prescription Drugs market
  • In-depth analysis of the market’s competitive landscape and detailed information about the vendors
  • The report also offers key market drivers, restrains, trends and opportunities with present and future impact on the market
  • Detailed information about the major players or manufacturers of the global Anti-Obesity Prescription Drugs market
  • Comprehensive analysis of the Anti-Obesity Prescription Drugs market segments based on its types, applications and end-use industry
Key Analytical Areas:
The report aims to offer a complete solution to various businesses operating in the Anti-Obesity Prescription Drugs market in making strategic decisions based on credible information and actionable insights. Thereby, the report covers various aspects of your requirements such as industry overview, market dynamics, regional analysis and competitive landscape. The report aims to provide insights to businesses in the Anti-Obesity Prescription Drugs market for numerous purposes such as:

     1. Strategic Decision Making:
With the help of this report, key decision makers can quickly analyze and identify growth opportunities in terms of numerous segments across various geographical regions. Thereby, this report enables organizations to identify and make strategic investments in specific market segments in order to gain maximum return on investment.

      2.  Actionable Insights:
The report offers a deep dive into how companies are leveraging market conditions to make the most in the Anti-Obesity Prescription Drugs market. Thereby, the report offers numerous actionable insights into the best practices and key success factors relevant in the Anti-Obesity Prescription Drugs market. Using the insights included in the report, businesses can make quick decisions to achieve success in business operations.

      3. Competitive Snapshot:
In addition, to detailed information on the companies operating in the Anti-Obesity Prescription Drugs market, the report also includes a competitive snapshot of all the companies covered in the report. Thereby, this offers a visual representation of how all the companies stand comparatively based on their competencies, geographic presence, market hold, years of operations, employee and financial strength, among others.

Manufacturers and Segments

  • BRISTOL-MYERS SQUIBB CO.
  • TAKEDA PHARMACEUTICAL
  • EISAI COMPANY
  • GLAXOSMITHKLINE PLC
  • PFIZER INC
  • SHIONOGI USA INC
  • VIVUS INC
  • ZAFGEN INC
  • NORGINE BV
  • BOEHRINGER INGELHEIM GMBH.
  • 7TM PHARMA
  • ZYDUS CADILA
  • AKRIMAX PHARMACEUTICALS
  • ZEALAND PHARMA
  • ARROWHEAD RESEARCH
  • Peripherally Acting Drugs
  • Centrally Acting Drugs
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summarysegment Form
     2.1. Global Anti-Obesity Prescription Drugs Market Snapshot
          2.1.1. Global Anti-Obesity Prescription Drugs Market By Mechanism of Action,2019
               2.1.1.1.Peripherally Acting Drugs
               2.1.1.2.Centrally Acting Drugs
          2.1.2. Global Anti-Obesity Prescription Drugs Market By Distribution Channel,2019
               2.1.2.1.Hospital Pharmacy
               2.1.2.2.Retail Pharmacy
               2.1.2.3.Online Pharmacy
          2.1.3. Global Anti-Obesity Prescription Drugs Market By End-use,2019
          2.1.4. Global Anti-Obesity Prescription Drugs Market By Geography,2019

3. Global Anti-Obesity Prescription Drugs Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Anti-Obesity Prescription Drugs Market Size (US$), By Mechanism of Action, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Mechanism of Action, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Mechanism of Action, 2020
     4.2. Global Anti-Obesity Prescription Drugs Market Size (US$), By Mechanism of Action, 2018 – 2028

5. Global Anti-Obesity Prescription Drugs Market Size (US$), By Distribution Channel, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By Distribution Channel, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By Distribution Channel, 2020
     5.2. Global Anti-Obesity Prescription Drugs Market Size (US$), By Distribution Channel, 2018 – 2028

6. Global Anti-Obesity Prescription Drugs Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Anti-Obesity Prescription Drugs Market Size (US$), By End-use, 2018 – 2028

7. Global Anti-Obesity Prescription Drugs Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Anti-Obesity Prescription Drugs Market Analysis, 2018 – 2028 
          7.2.1. North America Anti-Obesity Prescription Drugs Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Anti-Obesity Prescription Drugs Market Size (US$), By Mechanism of Action, 2018 – 2028
          7.2.3. North America Anti-Obesity Prescription Drugs Market Size (US$), By Distribution Channel, 2018 – 2028
          7.2.4. North America Anti-Obesity Prescription Drugs Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Anti-Obesity Prescription Drugs Market Analysis, 2018 – 2028 
          7.3.1.  Europe Anti-Obesity Prescription Drugs Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Anti-Obesity Prescription Drugs Market Size (US$), By Mechanism of Action, 2018 – 2028
          7.3.3. Europe Anti-Obesity Prescription Drugs Market Size (US$), By Distribution Channel, 2018 – 2028
          7.3.4. Europe Anti-Obesity Prescription Drugs Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Anti-Obesity Prescription Drugs Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Anti-Obesity Prescription Drugs Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Anti-Obesity Prescription Drugs Market Size (US$), By Mechanism of Action, 2018 – 2028
          7.4.3. Asia Pacific Anti-Obesity Prescription Drugs Market Size (US$), By Distribution Channel, 2018 – 2028
          7.4.4. Asia Pacific Anti-Obesity Prescription Drugs Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Anti-Obesity Prescription Drugs Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Anti-Obesity Prescription Drugs Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Anti-Obesity Prescription Drugs Market Size (US$), By Mechanism of Action, 2018 – 2028
          7.5.3. Latin America Anti-Obesity Prescription Drugs Market Size (US$), By Distribution Channel, 2018 – 2028
          7.5.4. Latin America Anti-Obesity Prescription Drugs Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Anti-Obesity Prescription Drugs Market Analysis, 2018 – 2028 
          7.6.1.  MEA Anti-Obesity Prescription Drugs Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Anti-Obesity Prescription Drugs Market Size (US$), By Mechanism of Action, 2018 – 2028
          7.6.3. MEA Anti-Obesity Prescription Drugs Market Size (US$), By Distribution Channel, 2018 – 2028
          7.6.4. MEA Anti-Obesity Prescription Drugs Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Anti-Obesity Prescription Drugs Providers
        8.4.1 BRISTOL-MYERS SQUIBB CO.
                8.4.1.1 Business Description
                8.4.1.2 BRISTOL-MYERS SQUIBB CO. Geographic Operations
                8.4.1.3 BRISTOL-MYERS SQUIBB CO. Financial Information
                8.4.1.4 BRISTOL-MYERS SQUIBB CO. Product Positions/Portfolio
                8.4.1.5 BRISTOL-MYERS SQUIBB CO. Key Developments
        8.4.2 TAKEDA PHARMACEUTICAL
                8.4.2.1 Business Description
                8.4.2.2 TAKEDA PHARMACEUTICAL Geographic Operations
                8.4.2.3 TAKEDA PHARMACEUTICAL Financial Information
                8.4.2.4 TAKEDA PHARMACEUTICAL Product Positions/Portfolio
                8.4.2.5 TAKEDA PHARMACEUTICAL Key Developments
        8.4.3 EISAI COMPANY
                8.4.3.1 Business Description
                8.4.3.2 EISAI COMPANY Geographic Operations
                8.4.3.3 EISAI COMPANY Financial Information
                8.4.3.4 EISAI COMPANY Product Positions/Portfolio
                8.4.3.5 EISAI COMPANY Key Developments
        8.4.4 GLAXOSMITHKLINE PLC
                8.4.4.1 Business Description
                8.4.4.2 GLAXOSMITHKLINE PLC Geographic Operations
                8.4.4.3 GLAXOSMITHKLINE PLC Financial Information
                8.4.4.4 GLAXOSMITHKLINE PLC Product Positions/Portfolio
                8.4.4.5 GLAXOSMITHKLINE PLC Key Developments
        8.4.5 PFIZER INC
                8.4.5.1 Business Description
                8.4.5.2 PFIZER INC Geographic Operations
                8.4.5.3 PFIZER INC Financial Information
                8.4.5.4 PFIZER INC Product Positions/Portfolio
                8.4.5.5 PFIZER INC Key Developments
        8.4.6 SHIONOGI USA INC
                8.4.6.1 Business Description
                8.4.6.2 SHIONOGI USA INC Geographic Operations
                8.4.6.3 SHIONOGI USA INC Financial Information
                8.4.6.4 SHIONOGI USA INC Product Positions/Portfolio
                8.4.6.5 SHIONOGI USA INC Key Developments
        8.4.7 VIVUS INC
                8.4.7.1 Business Description
                8.4.7.2 VIVUS INC Geographic Operations
                8.4.7.3 VIVUS INC Financial Information
                8.4.7.4 VIVUS INC Product Positions/Portfolio
                8.4.7.5 VIVUS INC Key Developments
        8.4.8 ZAFGEN INC
                8.4.8.1 Business Description
                8.4.8.2 ZAFGEN INC Geographic Operations
                8.4.8.3 ZAFGEN INC Financial Information
                8.4.8.4 ZAFGEN INC Product Positions/Portfolio
                8.4.8.5 ZAFGEN INC Key Developments
        8.4.9 NORGINE BV
                8.4.9.1 Business Description
                8.4.9.2 NORGINE BV Geographic Operations
                8.4.9.3 NORGINE BV Financial Information
                8.4.9.4 NORGINE BV Product Positions/Portfolio
                8.4.9.5 NORGINE BV Key Developments
        8.4.10 BOEHRINGER INGELHEIM GMBH.
                8.4.10.1 Business Description
                8.4.10.2 BOEHRINGER INGELHEIM GMBH. Geographic Operations
                8.4.10.3 BOEHRINGER INGELHEIM GMBH. Financial Information
                8.4.10.4 BOEHRINGER INGELHEIM GMBH. Product Positions/Portfolio
                8.4.10.5 BOEHRINGER INGELHEIM GMBH. Key Developments
        8.4.11 7TM PHARMA
                8.4.11.1 Business Description
                8.4.11.2 7TM PHARMA Geographic Operations
                8.4.11.3 7TM PHARMA Financial Information
                8.4.11.4 7TM PHARMA Product Positions/Portfolio
                8.4.11.5 7TM PHARMA Key Developments
        8.4.12 ZYDUS CADILA
                8.4.12.1 Business Description
                8.4.12.2 ZYDUS CADILA Geographic Operations
                8.4.12.3 ZYDUS CADILA Financial Information
                8.4.12.4 ZYDUS CADILA Product Positions/Portfolio
                8.4.12.5 ZYDUS CADILA Key Developments
        8.4.13 AKRIMAX PHARMACEUTICALS
                8.4.13.1 Business Description
                8.4.13.2 AKRIMAX PHARMACEUTICALS Geographic Operations
                8.4.13.3 AKRIMAX PHARMACEUTICALS Financial Information
                8.4.13.4 AKRIMAX PHARMACEUTICALS Product Positions/Portfolio
                8.4.13.5 AKRIMAX PHARMACEUTICALS Key Developments
        8.4.14 ZEALAND PHARMA
                8.4.14.1 Business Description
                8.4.14.2 ZEALAND PHARMA Geographic Operations
                8.4.14.3 ZEALAND PHARMA Financial Information
                8.4.14.4 ZEALAND PHARMA Product Positions/Portfolio
                8.4.14.5 ZEALAND PHARMA Key Developments
        8.4.15 ARROWHEAD RESEARCH
                8.4.15.1 Business Description
                8.4.15.2 ARROWHEAD RESEARCH Geographic Operations
                8.4.15.3 ARROWHEAD RESEARCH Financial Information
                8.4.15.4 ARROWHEAD RESEARCH Product Positions/Portfolio
                8.4.15.5 ARROWHEAD RESEARCH Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Anti-Obesity Prescription Drugs Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Anti-Obesity Prescription Drugs Market Revenue, By Mechanism of Action, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Anti-Obesity Prescription Drugs Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Anti-Obesity Prescription Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Anti-Obesity Prescription Drugs Market Revenue, By Mechanism of Action, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Anti-Obesity Prescription Drugs Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Anti-Obesity Prescription Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Anti-Obesity Prescription Drugs Market Revenue, By Mechanism of Action, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Anti-Obesity Prescription Drugs Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Anti-Obesity Prescription Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Anti-Obesity Prescription Drugs Market Revenue, By Mechanism of Action, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Anti-Obesity Prescription Drugs Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Anti-Obesity Prescription Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Anti-Obesity Prescription Drugs Market Revenue, By Mechanism of Action, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Anti-Obesity Prescription Drugs Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Anti-Obesity Prescription Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Anti-Obesity Prescription Drugs: Market Segmentation 
FIG. 2 Global Anti-Obesity Prescription Drugs Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Anti-Obesity Prescription Drugs Market, By Mechanism of Action, 2019 (US$ Mn) 
FIG. 5 Global Anti-Obesity Prescription Drugs Market, By Distribution Channel, 2019 (US$ Mn) 
FIG. 6 Global Anti-Obesity Prescription Drugs Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Anti-Obesity Prescription Drugs Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Anti-Obesity Prescription Drugs Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Anti-Obesity Prescription Drugs Providers, 2019
FIG. 11 Global Anti-Obesity Prescription Drugs Market Revenue Contribution, By Mechanism of Action, 2019 & 2028 (Value %) 
FIG. 12 Global Anti-Obesity Prescription Drugs Market Revenue Contribution, By Distribution Channel, 2019 & 2028 (Value %) 
FIG. 13 Global Anti-Obesity Prescription Drugs Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Anti-Obesity Prescription Drugs Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Anti-Obesity Prescription Drugs Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Anti-Obesity Prescription Drugs Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Anti-Obesity Prescription Drugs Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Anti-Obesity Prescription Drugs Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Anti-Obesity Prescription Drugs market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Anti-Obesity Prescription Drugs Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Anti-Obesity Prescription Drugs Market Value, By Segment1, 2018 – 2028
TABLE  North America Anti-Obesity Prescription Drugs Market Value, By Segment2, 2018 – 2028
TABLE  North America Anti-Obesity Prescription Drugs Market Value, By Country, 2018 – 2028
TABLE  Europe Anti-Obesity Prescription Drugs Market Value, By Segment1, 2018 – 2028
TABLE  Europe Anti-Obesity Prescription Drugs Market Value, By Segment2, 2018 – 2028
TABLE  Europe Anti-Obesity Prescription Drugs Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Anti-Obesity Prescription Drugs Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Anti-Obesity Prescription Drugs Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Anti-Obesity Prescription Drugs Market Value, By Country, 2018 – 2028
TABLE  Latin America Anti-Obesity Prescription Drugs Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Anti-Obesity Prescription Drugs Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Anti-Obesity Prescription Drugs Market Value, By Country, 2018 – 2028
TABLE  MEA Anti-Obesity Prescription Drugs Market Value, By Segment1, 2018 – 2028
TABLE  MEA Anti-Obesity Prescription Drugs Market Value, By Segment2, 2018 – 2028
TABLE  MEA Anti-Obesity Prescription Drugs Market Value, By Country, 2018 – 2028
TABLE  BRISTOL-MYERS SQUIBB CO.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  TAKEDA PHARMACEUTICAL: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  EISAI COMPANY: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  GLAXOSMITHKLINE PLC: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  PFIZER INC: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  SHIONOGI USA INC: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  VIVUS INC: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  ZAFGEN INC: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  NORGINE BV: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  BOEHRINGER INGELHEIM GMBH.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  7TM PHARMA: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  ZYDUS CADILA: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  AKRIMAX PHARMACEUTICALS: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  ZEALAND PHARMA: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  ARROWHEAD RESEARCH: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global Anti-Obesity Prescription Drugs Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Anti-Obesity Prescription Drugs Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Anti-Obesity Prescription Drugs Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Anti-Obesity Prescription Drugs Market, By Geography, 2019 (US$ Mn)
FIG.  Global Anti-Obesity Prescription Drugs Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Anti-Obesity Prescription Drugs Providers, 2016
FIG.  Global Anti-Obesity Prescription Drugs Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global Centrally Acting Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Anti-Obesity Prescription Drugs Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global Retail Pharmacy Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Online Pharmacy Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. Anti-Obesity Prescription Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Anti-Obesity Prescription Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Anti-Obesity Prescription Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Anti-Obesity Prescription Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Anti-Obesity Prescription Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Anti-Obesity Prescription Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Anti-Obesity Prescription Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Anti-Obesity Prescription Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Anti-Obesity Prescription Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Anti-Obesity Prescription Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Anti-Obesity Prescription Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Anti-Obesity Prescription Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Anti-Obesity Prescription Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Anti-Obesity Prescription Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Anti-Obesity Prescription Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Anti-Obesity Prescription Drugs Market Value, 2018 – 2028, (US$ Mn)